about
Targeting MAPK Signaling in Age-Related Macular DegenerationModulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs.Selumetinib in the treatment of non-small-cell lung cancer.Ribosomal S6 kinase (RSK) modulators: a patent review.Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.Exploring the cross talk between ER stress and inflammation in age-related macular degeneration.Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors.Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells.A Novel Role for Brain Natriuretic Peptide: Inhibition of IL-1β Secretion via Downregulation of NF-kB/Erk 1/2 and NALP3/ASC/Caspase-1 Activation in Human THP-1 Monocyte.Neuro-ophthalmic side effects of molecularly targeted cancer drugs.Electroacupuncture serum inhibits TNF‑α‑mediated chondrocyte inflammation via the Ras‑Raf‑MEK1/2‑ERK1/2 signaling pathway.Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-RafV600E inhibitors.3D Organotypic Culture Model to Study Components of ERK Signaling.Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade SignalingMechanisms of NF-κB p65 and strategies for therapeutic manipulation
P2860
Q26744185-FC790C24-1DEE-45A7-B4F7-2ACD9D958D7CQ37729599-931C5085-2951-4610-B083-553CA56E7C21Q38836927-BB8F727A-BCBC-4F8A-8CBE-685A2B496285Q38895271-6D649882-BDCC-43E2-8837-A6F4119571DBQ38956084-6F693AA7-DA5D-4B4C-8706-B382DFDED662Q38989374-D7296B9C-AA5C-4036-A9D6-0E2FCF836A08Q39580226-7CC80FAA-ACB6-40AA-8A22-932551F42666Q41105949-5B967C2E-A991-4C37-B64A-B618381ABE22Q41249331-331F4181-3F7B-430C-81AF-BE84DA319878Q41593165-E1B36DC0-E283-4A76-9114-95D0C81CC890Q42317064-ECF803A1-4A93-4A83-9539-73473EED0A91Q47625145-3E7858B1-0D2C-4A06-B76B-E3BB11C19F0BQ47890758-048B94CD-605D-4A29-A61B-E5A3732E3810Q50657303-12E6C921-3F05-4C71-807B-26BA25546D81Q52785661-10A24ADE-C998-4324-BE99-40ECA5E53A34Q57490053-DCF92D00-4476-46EA-BBAE-D41B6DB1345EQ59125995-9B17FA28-EC8D-4212-AC1D-392FE9B372DC
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Recent progress on MAP kinase pathway inhibitors.
@en
type
label
Recent progress on MAP kinase pathway inhibitors.
@en
prefLabel
Recent progress on MAP kinase pathway inhibitors.
@en
P1476
Recent progress on MAP kinase pathway inhibitors
@en
P2093
David E Uehling
P304
P356
10.1016/J.BMCL.2015.07.093
P407
P577
2015-08-01T00:00:00Z